Cardinal Health (CAH) Q3 2025: Segment Profit Up 21% as Pharma, Specialty, and Growth Businesses Accelerate
Cardinal Health delivered broad-based profit growth across all five segments in Q3, powered by specialty and new customer wins, while demonstrating strong tariff mitigation and disciplined capital allocation. The company’s raised guidance and resilient business mix set up for double-digit EPS growth in fiscal 2026, despite ongoing regulatory and macro headwinds.
Summary
- Specialty and Pharma Drive Momentum: Segment profit growth was led by specialty, new customer onboarding, and accretive acquisitions.
- Tariff Mitigation Actions Limit Exposure: Aggressive operational and pricing strategies are containing tariff risk, especially in GMPD.
- Guidance Raised on Broad-Based Strength: Management projects continued double-digit EPS growth into fiscal 2026.
Performance Analysis
Cardinal Health’s Q3 results reflected a step-change in profitability, with operating earnings up 21% and EPS rising 13% year-over-year. This was achieved despite reported revenue holding flat at nearly $55 billion, as the company lapped a major customer contract expiration. Excluding this headwind, underlying revenue growth was 19%, driven by robust demand in pharmaceutical and specialty solutions as well as the three “growth businesses” within the Other segment.
Pharma, which represents the bulk of the business, posted strong segment profit growth on the back of branded and specialty sales, successful onboarding of $10 billion in new customer revenue, and early contributions from recent acquisitions such as GI Alliance and Integrated Oncology Network. The Generics program, a key margin driver leveraging Red Oak Sourcing, also performed well. GMPD (Global Medical Products & Distribution), the turnaround segment, showed modest revenue growth and margin improvement from cost optimization, while the Other segment (At-Home Solutions, Nuclear, OptiFreight) delivered double-digit revenue and profit growth, supported by secular trends and tuck-in M&A.
- Operating Leverage Surges: Gross profit rose 10% while SG&A grew only 4%, reflecting disciplined cost control and integration of recent deals.
- Growth Businesses Outperform: At-Home Solutions, Nuclear, and OptiFreight each posted double-digit revenue gains, with profit up 22% in aggregate.
- Capital Deployment Accelerates: Over $3 billion was invested in acquisitions and share repurchases, while free cash flow remains robust.
The quarter’s results validate Cardinal’s strategic pivot toward higher-margin, specialty, and services businesses, while demonstrating resilience against external shocks.
Executive Commentary
"Our performance this quarter was driven by strong utilization trends and execution across our most significant business, pharmaceutical and specialty solutions, and our three growth businesses reported in other, which are becoming an increasingly important part of our overall mix. Most notably, the broad-based performance reflected profit growth from all five of our operating segments, an indication that our relentless focus on advancing our strategic priorities is delivering real, measurable impact."
Jason Haller, CEO
"Q3 was a strong financial quarter for us as we continued to do what we said we were going to do, invest in the business, drive growth in pharma and the three other growth businesses, and continue the turnaround of GMPD. Overall, we grew operating earnings by 21% and EPS by 13%, even while comparing against a prior period to the customer contract expiration and while executing and integrating our recent acquisitions."
Aaron Ault, CFO
Strategic Positioning
1. Specialty and Services Expansion
Specialty distribution and MSO platforms, management services organizations for physician practices, are now central to Cardinal’s long-term growth thesis. The company is layering in higher-margin, specialty-focused revenue streams, with GI Alliance and Integrated Oncology Network performing in line with expectations. The recent move into urology (Urology America, Potomac Urology) further diversifies the specialty footprint, while biopharma solutions and specialty networks deliver incremental profit.
2. Tariff Mitigation and Supply Chain Resilience
Cardinal is proactively addressing tariff risk, especially within GMPD, through a combination of domestic manufacturing expansion, supplier diversification, and AI-driven compliance. The majority of remaining gross tariff costs ($200–$300 million expected in fiscal 2026) are slated to be mitigated via price adjustments and operational actions, with management emphasizing that 95% of segment profit comes from businesses largely insulated from current tariff regimes.
3. Growth Businesses and Secular Tailwinds
The Other segment—comprising At-Home Solutions, Nuclear, and OptiFreight—continues to outpace core distribution, propelled by demographic trends and healthcare innovation. At-Home Solutions saw 12% revenue growth, with the Advanced Diabetes Supply Group acquisition expected to be immediately accretive. Nuclear’s 30%+ theranostics growth and new GE Healthcare partnerships underscore Cardinal’s positioning as a key radiopharmaceutical partner.
4. Customer Onboarding and Retention
Successful onboarding of $10 billion in new pharma customer revenue is a clear validation of Cardinal’s operational execution and competitive positioning. These wins are expected to drive further growth into fiscal 2026, offsetting prior contract losses and supporting a positive utilization environment.
5. Disciplined Capital Allocation
Cardinal’s capital deployment remains balanced between internal investment, M&A, share repurchases, and debt reduction. Over $7 billion has been invested in U.S. operations over two years, with a focus on automation, new distribution nodes, and technology to support long-term margin expansion.
Key Considerations
Cardinal Health’s Q3 showcased a business model increasingly anchored by specialty, services, and growth businesses, with robust tariff mitigation and capital discipline shaping the company’s risk profile and future opportunity set.
Key Considerations:
- Specialty Growth Outpaces Core Distribution: Specialty and services are now the primary profit engines, benefiting from secular healthcare trends and higher margins.
- Tariff Risk Is Concentrated and Managed: GMPD is the main exposure point, but mitigation actions and pricing power are containing the impact; 95% of profit is insulated.
- Operational Leverage Is Evident: Cost controls and SG&A discipline are driving margin expansion even as the company absorbs recent acquisitions.
- Customer Wins Signal Market Share Gains: The onboarding of $10 billion in new revenue is a durable tailwind for fiscal 2026 and beyond.
- Capital Allocation Supports Long-Term Growth: Investment in automation, domestic supply chain, and targeted M&A reinforce Cardinal’s competitive moat.
Risks
Tariff escalation remains a material risk for GMPD, with residual gross exposure of $200–$300 million in fiscal 2026, though most is expected to be mitigated via price and operations. Regulatory volatility, especially around drug pricing and healthcare reimbursement, could pressure margins or disrupt business models. Macro softness or sudden shifts in pharmaceutical utilization, while historically limited, could pose downside risk if secular trends reverse or competition intensifies in specialty and services.
Forward Outlook
For Q4 2025, Cardinal Health guided to:
- EPS in the range of $8.05 to $8.15 for the full year (raised and narrowed guidance)
- Adjusted free cash flow at the high end of prior guidance, approximately $1.5 billion
For full-year 2026, management signaled:
- Double-digit non-GAAP EPS growth, driven by specialty, new customer wins, and growth businesses
Management highlighted several factors that support the outlook:
- Positive utilization trends and secular demand in specialty and services
- Operational improvements and tariff mitigation in GMPD
- Accretive impact from recent acquisitions and continued capital discipline
Takeaways
Cardinal Health’s Q3 results reinforce its transformation toward a higher-margin, specialty-driven business with strong operational execution and risk management.
- Specialty and Growth Businesses Are Now the Core Profit Drivers: With pharma and specialty solutions leading segment profit growth and new customer onboarding, Cardinal is less reliant on legacy distribution margin.
- Tariff Exposure Is Contained and Manageable: Aggressive operational actions and pricing flexibility are limiting the financial impact, with most profit coming from insulated segments.
- Outlook for Fiscal 2026 Is Robust: Management’s confidence in double-digit EPS growth is supported by secular healthcare trends, recent M&A, and a resilient, diversified business mix.
Conclusion
Cardinal Health’s Q3 2025 performance underscores a business in transition, leveraging specialty and growth businesses for profitability while demonstrating strong operational and capital discipline. With tariff risk largely ring-fenced and new customer wins fueling forward momentum, the company is positioned for durable double-digit EPS growth into fiscal 2026.
Industry Read-Through
Cardinal Health’s results highlight the growing importance of specialty distribution, MSO platforms, and value-added services in the healthcare supply chain landscape. The company’s ability to offset regulatory and tariff headwinds through operational agility and pricing power offers a playbook for peers facing similar risks. Secular tailwinds in at-home care, nuclear medicine, and logistics suggest continued outperformance for diversified healthcare distributors that invest in automation and specialty capabilities. For the broader sector, the quarter signals that scale, supply chain resilience, and specialty focus are critical differentiators in an increasingly complex and regulated environment.